{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:25:56Z","timestamp":1791530756493,"version":"4.3.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We assessed changes in glycemic control and person-reported outcome measures (PROMs) with t:slim X2 insulin pump with Control-IQ technology use among historically minoritized youth who are least likely to access hybrid closed loop (HCL) technology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This single-arm, prospective pilot study enrolled 15 publicly insured, insulin pump-na\u00efve, non-Hispanic Black youth ages 6 to &lt;21 years with type 1 diabetes and hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) \u226510% in a 6-month study of HCL use. The primary outcome was absolute change in time in range (TIR) (70\u2013180\u2009mg\/dL). Secondary outcomes included other continuous glucose monitor metrics, PROMs, and diabetic ketoacidosis (DKA) incidence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      For 13 youth (median 14.8 years, 53.3% female, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      11.7%) who completed the study, baseline TIR of 12.3% (6.3\u201327.1%) increased 23.7%-points (16.9, 30.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) or 5.7\u2009h per day. Percent time &gt;250\u2009mg\/dL decreased 33.9%-points (\u221244.8, \u221223.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) or 8.1\u2009h per day from a baseline of 69.4% (51.6, 84.0%). Median time in HCL was 78.3% (59.7, 87.3%). Youth received 10.1 (9.2, 11.9) boluses per day, 71.7% (63.8, 79.3%) of which were HCL-initiated autoboluses. Diabetes-specific quality of life increased among parents (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and youth (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.004), and diabetes distress decreased in both groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.005). Improvements in glycemia did not correlate with any baseline youth or parent PROMs. DKA was high at baseline (67 episodes\/100-person years) and did not increase during the intervention (72 episodes\/100-person years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.78).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Improvements in glycemic control and quality of life exceeding pivotal trial findings without increased safety risks among historically minoritized youth emphasize the need for equitable access to HCL systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov:<\/jats:title>\n                    <jats:p>\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:uri>\n                      ID (NCT04807374).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2023.0450","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:00:25Z","timestamp":1709694025000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Hybrid Closed Loop Systems Improve Glycemic Control and Quality of Life in Historically Minoritized Youth with Diabetes"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-9774","authenticated-orcid":false,"given":"Brynn E.","family":"Marks","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."},{"name":"Department of Pediatrics, Perelman School of Medicine, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-4193","authenticated-orcid":false,"given":"Jody B.","family":"Grundman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Children's National Medical Center, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Meighan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Monaghan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Children's National Medical Center, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Streisand","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Children's National Medical Center, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Perkins","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Children's National Medical Center, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0345"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0257"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0077"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0340"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/cd21-0028"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2121"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-3063"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0558"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0201.pub"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0524"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsz083"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsx146"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsz018"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004736"},{"key":"e_1_3_5_16_2","article-title":"Differences in positive expectancy of hybrid closed loop (HCL) insulin delivery systems do not explain racial differences in HCL use","volume":"32","author":"Grundman JB","year":"2023","unstructured":"Grundman JB, , Perkins A, , Monaghan M, et al. Differences in positive expectancy of hybrid closed loop (HCL) insulin delivery systems do not explain racial differences in HCL use. J Clin Transl Endocrinol, 2023; 32:100319.","journal-title":"J Clin Transl Endocrinol"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13930"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12682"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907863"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0172"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2205225"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0384"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0646"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0162"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00996-7"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1971"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610187"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac034"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2250"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13213"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14252"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.13994"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2019.10.004"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12962"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0532"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.3965"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12777"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0694-2"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0338"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0393"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2023.0450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:14:27Z","timestamp":1777400067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2023.0450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1089\/dia.2023.0450"],"URL":"https:\/\/doi.org\/10.1089\/dia.2023.0450","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}